PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1320152
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1320152
Cell Banking Outsourcing Market size was valued at USD 9,701.4 Million in 2022, expanding at a CAGR of 17.9% from 2023 to 2030.
Cell banking outsourcing is the practice of contracting out the establishment, operation, and storage of cell banks to external firms or service providers. Cell banks are collections of cell lines or cell cultures used in biopharmaceutical research, drug development, regenerative medicine, and bio-production. Cell banking outsourcing enables businesses to benefit from the experience and infrastructure of specialist service providers. These service providers have substantial experience in cell banking processes such as cell line generation, characterization, cryopreservation, and storage. Cell banking outsourcing offers businesses flexibility and scalability. Outsourcing enables simple scaling up or down without the requirement for large capital investments when the demand for mobile banking services varies.
Increasing adoption of stem cell therapies and growing demand for monoclonal antibodies along with effective biopharmaceuticals are the major factors, driving growth of the market.
In the field of regenerative medicine and disease treatment, stem cell therapies are gaining a lot of focus. With their capacity to differentiate into a variety of cell types, stem cells can be employed to create cutting-edge treatments for diseases like cancer, cardiovascular problems, neurological issues, and more. The development and production of stem cell-based therapies require robust cell banking processes to ensure a consistent and reliable supply of cells. In 2020, an estimated 1,806,590 new cases of cancer will be diagnosed in the United States and 606,520 people will die from the disease, according to the national cancer institute. Thatswhy, the use of monoclonal antibodies (mAbs) in the treatment of a wide range of illnesses, such as cancer, autoimmune conditions, and infectious diseases, has become essential. The increasing demand for biopharmaceuticals and stem cell therapies, and the complex regulatory landscape are the factors that provide growth opportunities for the market. However, the High cost of storing cells restricted the growth of the market.
The Global Cell Banking Outsourcing Market is segmented on the basis of Product Type, Cell Type, Application, and Region.
The market is divided into three categories based on product type: Master Cell Banking, Working Cell Banking, and Viral Cell Banking. Master Cell Banking dominates the market growth. A group of cells produced from a single source that is utilized as a starting point for the manufacturing of biological products, such as vaccines, medicines, and cell-based therapies, is referred to as master cell banking.
The market is divided into two categories based on Cell type: Stem Cell and Non-Stem Cell. Stem Cell type dominates the market growth. As the area of regenerative medicine and cell-based therapeutics progresses, there is a growing demand for stem cell banking services. Through stem cell banking, individuals can keep their own stem cells or the stem cells of a family member for potential use in medical therapies in the future.
The market is divided into two categories based on Phase: Bank Storage, Bank Characterization & Testing, Bank Preparation. The Bank Storage sector dominates the market and is likely to maintain its dominance during the forecast period. The bank storage sector, in terms of cell banking outsourcing, refers to the specialized facilities and services in the care of cell bank storage and maintenance. These facilities, which include master cell banks and stem cell banks, are critical in ensuring the long-term preservation and integrity of cells.
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the growth of Cell Banking Outsourcing Market, due to rising incidences of metabolic disorders such as Parkinson's, Alzheimer's, and various other types of cancers, which can be treated by gene therapy. In North America, metabolic illnesses, such as Parkinson's disease, Alzheimer's disease, and numerous malignancies, place an enormous demand on health. These diseases are very common in the area, which increases the demand for cutting-edge treatments like gene therapy. According to Alzheimer's Association, the number of Americans living with Alzheimer's is growing and upward fast. More than 6 million Americans of all ages have Alzheimer's. Also, an estimated 6.7 million Americans age 65 and older are living with Alzheimer's in 2023. Seventy-three percent are age 75 or older. Europe is the second largest market for Cell Banking Outsourcing. Europe is known for having a strong life sciences and healthcare infrastructure. Numerous prestigious academic institutions, biotechnology firms, and prominent research organizations can be found in the area, and they all actively contribute to cutting-edge development and research.
The competitive landscape in the cell banking outsourcing market continues to develop as the demand for cell-based therapies and regenerative medicine advances. Those companies compete on the basis of their knowledge, quality assurance procedures, adherence to regulations, and service offers. They serve academic institutions, research organizations, and pharmaceutical and biotechnology corporations that are looking for dependable and secure outsourcing solutions for their cell banking requirements. For example, in August.2022, Life sciences start-up Cryoniss, which provides temperature-controlled biological sample storage and logistics solutions, has teamed up with microbiology testing lab and contract research organization Perfectos Biomed Group to launch cell culture services in a move that strengthens the two Cheshire-based companies' relationship and significantly expands Cryoniss' capabilities.
In December 2021, The successful commercialization of a biopharmaceutical product begins with a robust and productive cell line. Inefficient cell-line development (CLD) can lead to costly delays and roadblocks. For that reason, small, new, and virtual companies and even established and mid-size companies often seek the support of outsourcing partners to develop their cell lines.